Literature DB >> 21519038

Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study.

Sunil K Agarwal1, Christy L Avery, Christie M Ballantyne, Diane Catellier, Vijay Nambi, Justin Saunders, A Richey Sharrett, Josef Coresh, Gerardo Heiss, Ron C Hoogeveen.   

Abstract

BACKGROUND: Application of cardiac troponin T (cTnT) as a marker of myocyte damage requires knowledge of its measurement variability. Using a highly sensitive assay for measurement, we evaluated the long-term storage stability of plasma cTnT at -70 °C and the sources of cTnT variability.
METHODS: Samples from the Atherosclerosis Risk in Communities study collected in 1996-1998 and 2005-2006 were assayed centrally to quantify variability in cTnT attributable to processing (replicates from same blood draw, n = 87), laboratory (replicates after freeze thaw, n = 29), short-term (n = 40) and long-term biological variation (repeat visit, n = 38), and degradation in frozen storage (n = 7677).
RESULTS: Approximately 30% of this population-based cohort had cTnT concentrations below the detection limit (3 ng/L). Reliability coefficients for all paired comparisons exceeded 0.93 except for samples drawn 8 years apart (r = 0.36). Sources of cTnT variation (as CVs) were: laboratory, 2.1% and 11.2% in those with and without heart failure, respectively; processing, 18.3%; biological, 16.6% at 6 weeks and 48.4% at 8 years. The reference change value at 6 weeks (68.5%) indicated that 4 samples are needed to determine a homeostatic set point within ±25%. The estimated cTnT degradation rate over the first year in long-term frozen storage was 0.36 ng/L per year.
CONCLUSIONS: cTnT was detectable in approximately 70% of community-dwelling middle-aged study participants and stable in -70 °C storage. The variability in cTnT attributable to 1 freeze-thaw cycle is of small magnitude. The observed high laboratory and intraindividual (biological) reliability of cTnT support its use for population-based research, and in clinical settings that rely on classification and serial measurements.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519038      PMCID: PMC4928588          DOI: 10.1373/clinchem.2010.159350

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  22 in total

1.  Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes.

Authors:  Y Sato; T Yamada; R Taniguchi; K Nagai; T Makiyama; H Okada; K Kataoka; H Ito; A Matsumori; S Sasayama; Y Takatsu
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

2.  Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay.

Authors:  Vlad C Vasile; Amy K Saenger; Jean M Kroning; Allan S Jaffe
Journal:  Clin Chem       Date:  2010-05-14       Impact factor: 8.327

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases.

Authors:  A H Wu; F S Apple; W B Gibler; R L Jesse; M M Warshaw; R Valdes
Journal:  Clin Chem       Date:  1999-07       Impact factor: 8.327

5.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

6.  Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure.

Authors:  K Setsuta; Y Seino; N Takahashi; T Ogawa; K Sasaki; A Harada; T Takano; H Kishida; H Hayakawa
Journal:  Am J Cardiol       Date:  1999-09-01       Impact factor: 2.778

7.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.

Authors:  E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-31       Impact factor: 91.245

8.  Sensitive troponin I assay in early diagnosis of acute myocardial infarction.

Authors:  Till Keller; Tanja Zeller; Dirk Peetz; Stergios Tzikas; Alexander Roth; Ewa Czyz; Christoph Bickel; Stephan Baldus; Ascan Warnholtz; Meike Fröhlich; Christoph R Sinning; Medea S Eleftheriadis; Philipp S Wild; Renate B Schnabel; Edith Lubos; Nicole Jachmann; Sabine Genth-Zotz; Felix Post; Viviane Nicaud; Laurence Tiret; Karl J Lackner; Thomas F Münzel; Stefan Blankenberg
Journal:  N Engl J Med       Date:  2009-08-27       Impact factor: 91.245

9.  Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure.

Authors:  Junnichi Ishii; Wei Cui; Fumihiko Kitagawa; Takahiro Kuno; Yuu Nakamura; Hiroyuki Naruse; Yoshihisa Mori; Takashi Ishikawa; Youichi Nagamura; Takeshi Kondo; Hisaji Oshima; Masanori Nomura; Kouji Ezaki; Hitoshi Hishida
Journal:  Clin Chem       Date:  2003-12       Impact factor: 8.327

10.  On the calculation of a "reference change" for comparing two consecutive measurements.

Authors:  E K Harris; T Yasaka
Journal:  Clin Chem       Date:  1983-01       Impact factor: 8.327

View more
  42 in total

1.  Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death.

Authors:  John W McEvoy; Yuan Chen; Chiadi E Ndumele; Scott D Solomon; Vijay Nambi; Christie M Ballantyne; Roger S Blumenthal; Josef Coresh; Elizabeth Selvin
Journal:  JAMA Cardiol       Date:  2016-08-01       Impact factor: 14.676

2.  High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study.

Authors:  Andrea L C Schneider; Andreea M Rawlings; A Richey Sharrett; Alvaro Alonso; Thomas H Mosley; Ron C Hoogeveen; Christie M Ballantyne; Rebecca F Gottesman; Elizabeth Selvin
Journal:  Eur Heart J       Date:  2014-03-30       Impact factor: 29.983

3.  The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study.

Authors:  Anna Fretz; Andrea L C Schneider; John W McEvoy; Ron Hoogeveen; Christie M Ballantyne; Josef Coresh; Elizabeth Selvin
Journal:  Am J Epidemiol       Date:  2016-02-08       Impact factor: 4.897

4.  High-Sensitivity Cardiac Troponin T and Risk of Hypertension.

Authors:  John W McEvoy; Yuan Chen; Vijay Nambi; Christie M Ballantyne; A Richey Sharrett; Lawrence J Appel; Wendy S Post; Roger S Blumenthal; Kunihiro Matsushita; Elizabeth Selvin
Journal:  Circulation       Date:  2015-07-07       Impact factor: 29.690

Review 5.  Lipid lowering with PCSK9 inhibitors.

Authors:  Razvan T Dadu; Christie M Ballantyne
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

6.  Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study.

Authors:  Anandita Agarwala; Salim Virani; David Couper; Lloyd Chambless; Eric Boerwinkle; Brad C Astor; Ron C Hoogeveen; Joe Coresh; A Richey Sharrett; Aaron R Folsom; Tom Mosley; Christie M Ballantyne; Vijay Nambi
Journal:  Atherosclerosis       Date:  2016-08-25       Impact factor: 5.162

7.  Analytical and biological variability in biomarker measurement in the Hispanic Community Health Study/Study of Latinos.

Authors:  Bharat Thyagarajan; Annie Green Howard; Ramon Durazo-Arvizu; John H Eckfeldt; Marc D Gellman; Ryung S Kim; Kiang Liu; Armando J Mendez; Frank J Penedo; Gregory A Talavera; Marston E Youngblood; Lihui Zhao; Daniela Sotres-Alvarez
Journal:  Clin Chim Acta       Date:  2016-10-15       Impact factor: 3.786

8.  High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Kristian B Filion; Sunil K Agarwal; Christie M Ballantyne; Maria Eberg; Ron C Hoogeveen; Rachel R Huxley; Laura R Loehr; Vijay Nambi; Elsayed Z Soliman; Alvaro Alonso
Journal:  Am Heart J       Date:  2014-10-22       Impact factor: 4.749

9.  Troponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).

Authors:  Aaron R Folsom; Pamela L Lutsey; Vijay Nambi; Christopher R deFilippi; Susan R Heckbert; Mary Cushman; Christie M Ballantyne
Journal:  Vasc Med       Date:  2014-02       Impact factor: 3.239

10.  Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality.

Authors:  Oludamilola W Oluleye; Aaron R Folsom; Vijay Nambi; Pamela L Lutsey; Christie M Ballantyne
Journal:  Ann Epidemiol       Date:  2012-12-08       Impact factor: 3.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.